This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McNicholas, P. M.
Right arrow Articles by Black, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNicholas, P. M.
Right arrow Articles by Black, T. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 79-83, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.79-83.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Effects of Mutations in Ribosomal Protein L16 on Susceptibility and Accumulation of Evernimicin

Paul M. McNicholas,* Paul A. Mann, David J. Najarian, Lynn Miesel, Roberta S. Hare, and Todd A. Black

Schering Plough Research Institute, Kenilworth, New Jersey 07033

Received 16 June 2000/Returned for modification 21 August 2000/Accepted 12 October 2000

Chemical mutagenesis of Staphylococcus aureus RN450 generated two strains that displayed a stable reduction (30- to 60-fold) in susceptibility to evernimicin. Cell-free translation reactions demonstrated that the resistance determinant was located in the ribosomal fraction. Compared to ribosomes isolated from a wild-type strain, ribosomes from the mutant strains displayed an 8- to 10-fold reduction in affinity for [14C]evernimicin. In contrast, the mutants displayed no alteration in either binding affinity or in vitro susceptibility to erythromycin. Exponential cultures of the mutant strains accumulated significantly less [14C]evernimicin than the wild-type strain, suggesting that accumulation is dependent on the high affinity that evernimicin displays for its binding site. Sequencing rplP (encodes ribosomal protein L16) in the mutant strains revealed a single base change in each strain, which resulted in a substitution of either cysteine or histidine for arginine at residue 51. Introduction of a multicopy plasmid carrying wild-type rplP into the mutant strains restored sensitivity to evernimicin, confirming that the alterations in rplP were responsible for the change in susceptibility. Overexpression of the mutant alleles in S. aureus RN450 had no effect on susceptibility to evernimicin, demonstrating that susceptibility is dominant over resistance.


* Corresponding author. Mailing address: Schering Plough Research Institute, Bldg. K15-4-4700, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Phone: (908) 740-7644. Fax: (908) 740-3918. E-mail: paul.mcnicholas{at}spcorp.com.


Antimicrobial Agents and Chemotherapy, January 2001, p. 79-83, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.79-83.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Boll, R., Hofmann, C., Heitmann, B., Hauser, G., Glaser, S., Koslowski, T., Friedrich, T., Bechthold, A. (2006). The Active Conformation of Avilamycin A Is Conferred by AviX12, a Radical AdoMet Enzyme. J. Biol. Chem. 281: 14756-14763 [Abstract] [Full Text]  
  • Kofoed, C. B., Vester, B. (2002). Interaction of Avilamycin with Ribosomes and Resistance Caused by Mutations in 23S rRNA. Antimicrob. Agents Chemother. 46: 3339-3342 [Abstract] [Full Text]  
  • Zarazaga, M., Tenorio, C., Del Campo, R., Ruiz-Larrea, F., Torres, C. (2002). Mutations in Ribosomal Protein L16 and in 23S rRNA in Enterococcus Strains for Which Evernimicin MICs Differ. Antimicrob. Agents Chemother. 46: 3657-3659 [Abstract] [Full Text]